Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11963956B2 · kind B2 · utility
0Cited by
31References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 21, 2022 |
| Grant date | Apr 23, 2024 |
| Priority date | — |
| Expiry date | Mar 21, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.